Protein-based therapeutic approaches targeting death receptors (Q35091424)

6 August 2017

1 reference

title

Protein-based therapeutic approaches targeting death receptors (English)

1 reference

6 August 2017

2

Jürg Tschopp

1 reference

6 August 2017

Lars E French

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Cell Death & Differentiation

6 August 2017

published in

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

117-123

1 reference

Apoptosis control by death and decoy receptors

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Does graft-versus-host disease attack epithelial stem cells?

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Increased Fas antigen on T cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Multiple sclerosis: Fas signaling in oligodendrocyte cell death

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Lethal effect of the anti-Fas antibody in mice

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4401185

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4401185

1 reference

release_5gxpwfovunc2nh7hw6okomhps4

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5gxpwfovunc2nh7hw6okomhps4

24 November 2022

mapped directly with Wikidata item

1 reference